Turning Pennies into dollars: (OTCBB:NNVC) NanoViricides, Inc.
Are you a public company looking for exposure?
Contact RealPennies.com - 212-662-2147
For more info: http://www.realpennies.com/otc/nnvc
NanoViricides, Inc. Submits a Grant Application for Broad-Spectrum Nanoviricides
(OTCBB:NNVC) NanoViricides, Inc.
Sunday February 1, 11:20 pm ET
If Approved, Could Finance Dengue and Ebola/Marburg Drug Development
WEST HAVEN, Conn.-NanoViricides, Inc. , said that it has recently submitted a grant application to the Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs. If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure against bio-terrorism and emerging infectious diseases such as Ebola/Marburg, and Dengue.
The Company has already demonstrated that some of the nanoviricides we have created are broad-spectrum. It is believed that viruses are unlikely to escape such broad-spectrum nanoviricides by mutation because such mutations would also cause a loss of infectivity.
At present, other MCM efforts have generally resulted in highly specific one-bug-one-drug type of therapies, such as vaccines, antibodies, certain anti-sense therapeutics, and some other antivirals. Thus, a large number of drugs, vaccines and antibodies would need to be stockpiled to mitigate the threat from a countless number of pathogens and their known mutants. Further, if a virus mutates further, then most such agents are likely to become ineffective. Mutations are common in many viruses, and can also be genetically engineered to produce devastating bio-terrorism agents.
The Company has assembled a strong team comprising several renowned Institutions and Companies for the proposed project. There is no guarantee that the grant application will result in any funding.
Ebola viruses cause devastating disease with mortality rates as high as 90%. Dengue has now become endemic in most of the tropical world, and is becoming an important public health threat in the United States. A second infection from an unrelated dengue virus subtype can be life-threatening, resulting in dengue hemorrhagic fever or dengue shock syndrome . There is currently no drug or vaccine available for dengue viruses. The worldwide market for a dengue treatment could be possibly in the billions of dollars.
About NanoViricides:
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide? class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the ?Management?s Discussion and Analysis? section of the Company?s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
Contact:
NanoViricides, Inc. Amanda Schuon, 310-550-7200 info@nanoviricides.com Source: NanoViricides, Inc.
Profile for NanoViricides, Inc.
NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus , Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company’s products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide ... Detailed NNVC Company Description...
LAST $0.71 USD
Realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on
http://www.realpennies.com/start.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.
RealPennies.com
Phone: 212-662-2147
info [at] realpennies.com
No comments:
Post a Comment